Abstract
This paper attempts to better define the areas of conflict and agreement between value ethics and the theoretical ethics of the market processes at work in the biotechnology industry. Despite the apparent lack of ethics in an oligopolistically competitive pharmaceuticals industry, the paper concludes that the current stage of development of the medical biotechnology subindustry offers unparalleled opportunities for ethical systems to influence the market-based development of biotechnology. Ethical conversations between doctors and biologists with ethicists can help the market absorb more of the reflective wisdom that ethics brings when discussing such issue areas as justice, patents of the human genome, and modifications of the human genome. If conversations between ethicists and biotechnological managers and doctors are successful the metaphors of market-based financing may be refined and the knowledge base of the good increased.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Biotechnology
Billingham, John (ed.): 1982, Life in the Universe (The MIT Press, Cambridge, Mass).
Cioffi, Joseph A.: 1993 (Aug), ‘Application of Biotechnology and Transgenic Animals toward the Study of Growth Hormone’, American Journal of Clinical Nutrition, 2968–2989.
Edmondson, Gail, John Carey and Joan O'C. Hamilton: 1996 (Sept 30), ‘Science and Technology, Biotech, Europe's Ace Gene Hunter, Can Daniel Cohen's Startup Outrun U.S. Rivals?’, Business Week, 86, 88.
Fisher, Lawrence M.: 1996 (Sept 26), ‘Genetics Institute in Deal to Share Biochemical Library’, New York Times, D1, D4.
Garrett, Laurie: 1994, The Coming Plague (Farrar, Staus and Giroux, New York).
Gladwell, Malcolm: 1991 (Aug 27), ‘Animals Altered to Produce Medicine in Milk’, Washington Post.
Kirkland, Richard I. Jr.: 1994 (Feb 21), ‘Why We Will Live Longer... and What It Will Mean’, Fortune 129(4), 66–78.
Lawrence M. Fisher: 1996 (July 3), Drug Makers Set to License Data on Genes, Agreements' Value is Put at $90 Million’, New York Times, D1, D3.
McGinley, Laurie: 1994 (Dec 14), ‘Rhone-Poulenc Cancer Drug Fails FDA Vote’, Wall Street Journal, A1, B5.
Maugh, Thomas H.: 1991 (Aug 27), ‘Geneticists Modify Goats to Harvest Pharmaceuticals’, Los Angeles Times, A1.
New Scientist: 1994 (Mar 26), ‘Millions at Stake over “Human” Mouse’, New Scientist, 4–5.
New York Times: 1992 ( July 1), ‘Patent Office to Review Genetically Altered Tomato’, New York Times, pC3, pD3.
Smith, Geoffrey and John Carey: 1996 (Oct 21), ‘The Haystack Gets Smaller’, Business Week, 72, 76.
Stipp, David: 1991 (Aug 27), ‘Animals Altered to Make Drugs in Their Milk’, Wall Street Journal, B1.
Wall Street Journal: 1992 ( June 26), ‘Company Gets U.S. Patent for Novel Celery Product’, Wall Street Journal, pB6.
Watson, James D., Michael Gilman, Jan Witkowski and Mark Zoller: 1993, Recombinant DNA, 2nd ed. (Scientific American Book, distributed by W.H. Freeman and Company).
Zurer, Pamela S.: 1994 (Mar 14), ‘Scientists Confront Ethical Challenges Posed by Progress in Biotechnology’, Chemical & Engineering News 72(11), 20–21.
Ethics
Anonymous: 1977 (May 19), ‘The Implications of Recombinant DNA’, Origins, 772.
Friend, Bishop: 1995 ( Jan 19), ‘Frontiers of Genetic Research: Science and Religion’, Origin, 523.
Gadamer, H. G.: 1986, The Idea of the Good in Platonic-Aristotelian Philosophy (Yale University, New Haven).
Gadamer, H. G.: 1989, Truth and Method (Crossroad Publishing Company, New York.
Jones, T. M.: 1995, ‘Instrumental Stakeholder Theory: A Synthesis of Ethics and Economics’, Academy of Management Review 20, 404–437.
Kohlberg, L.: 1969, ‘Stage and Sequence’, in D. Goslin (ed.), Handbook of Socialisation Theory and Research (Rand McNally, Chicago).
Kohlberg, L.: 1979, ‘Moral Stages and Moralization’, in T. Likona (ed.), Moral Development and Behavior (Holt, Rinehart & Winston, New York), pp. 31–53.
Kohlberg, L.: 1982, ‘Essays on Moral Development’, The Philosophy of Moral Development, Vol. 1 (Harper and Row, San Francisco).
Logsdon, Jeanne M. and Kristi Yuthaus: 1995 (Nov),’ Corporate Social Performance and Moral Development’, Proceedings of the 1995 Business Ethics Meeting, From the University to the Marketplace: The Business Ethics Journal (St. John's University, New York), pp. 76–87.
Martone, Marilyn: 1996 (Oct), ‘The Ethics of the Economics of Patenting the Human Genome’, Working paper (St. John's University, New York).
McGuire, Stephen: 1995 (Nov), ‘A Compromise Between Reason and Virtue’, Proceedings of the 1995 Business Ethics Meeting, From the University to the Marketplace: The Business Ethics Journey (St. John's University, New York), pp. 271–293.
Macleod, A. M.: 1993, ‘Moral Philosophy and Business Ethics: The Priority of the Political’, Applied Ethics (Blackwell, Cambridge, Mass), pp. 222–228.
Nelson, J. Robert: 1994, On the New Frontiers of Genelics and Religion (William B. Eerdmans Publishing Company, Grand Rapids, Michigan).
Rosner, Mary and T. R. Johnson: 1995 (Fall), ‘Telling Stories: Metaphors of the Human Genome Project’, Hypatia, 104–129.
Solomon, R. C.: 1993, ‘Corporate Roles, Personal Virtues; an Aristotelian Approach to Business Ethics’, Applied Ethics (Blackwell, Cambridge), pp. 201–221.
Trevino, L. K.: 1986, ‘Ethical Decision Making in Organizations: A Person-Situation Ineractionist Model’, Academy of Management Review 11, 601–617.
Winkler, E. R.: 1993, ‘From Kantianism to Contextualism: The Rise and Fall of the Paradigm Theory in Bioethics’, Applied Ethics (Blackwell, Cambridge, Mass), pp. 343–345.
Rights and permissions
About this article
Cite this article
Flowers, E.B. The Ethics and Economics of Patenting the Human Genome. Journal of Business Ethics 17, 1737–1745 (1998). https://doi.org/10.1023/A:1006044224482
Issue Date:
DOI: https://doi.org/10.1023/A:1006044224482